Transenterix Inc (TRXC) Downgraded to “Sell” at Zacks Investment Research
Transenterix Inc (NASDAQ:TRXC) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. “
Separately, B. Riley downgraded Transenterix to a “neutral” rating and set a $0.70 target price on the stock. in a report on Tuesday, May 16th.
Transenterix (NASDAQ TRXC) traded down 1.4000% during trading on Tuesday, reaching $0.6902. The company’s stock had a trading volume of 427,181 shares. The company’s 50 day moving average price is $0.68 and its 200-day moving average price is $0.95. The stock’s market cap is $91.37 million. Transenterix has a 1-year low of $0.45 and a 1-year high of $2.33.
COPYRIGHT VIOLATION NOTICE: “Transenterix Inc (TRXC) Downgraded to “Sell” at Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/transenterix-inc-trxc-downgraded-to-sell-at-zacks-investment-research.html.
In other Transenterix news, Director Richard C. Pfenniger, Jr. bought 100,000 shares of Transenterix stock in a transaction on Tuesday, May 16th. The shares were purchased at an average price of $0.54 per share, with a total value of $54,000.00. Following the acquisition, the director now owns 148,000 shares in the company, valued at approximately $79,920. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
An institutional investor recently bought a new position in Transenterix stock. LMR Partners LLP acquired a new stake in shares of Transenterix Inc (NASDAQ:TRXC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 266,053 shares of the company’s stock, valued at approximately $189,000. LMR Partners LLP owned 0.18% of Transenterix at the end of the most recent reporting period.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.